Kisspeptin-10 — Research, Dosing & Price Guide

Kisspeptin-10 is a truncated bioactive fragment of the kisspeptin family of peptides, which are the master regulators of reproductive hormone release. It activates the KISS1R receptor on GnRH neurons in the hypothalamus, triggering a potent surge of gonadotropin-releasing hormone and downstream LH/FSH secretion. It is studied for fertility, hypogonadism, and sexual health applications.

Kisspeptin-10 binds to the KISS1R (GPR54) receptor on GnRH-expressing neurons in the hypothalamic arcuate and anteroventral periventricular nuclei. This activates phospholipase C signaling, increases intracellular calcium, and triggers pulsatile GnRH release from nerve terminals in the median eminence. GnRH then stimulates pituitary gonadotrophs to release LH and FSH. Kisspeptin is the most upstream activator of the reproductive axis — it sits above GnRH in the hormonal cascade. This makes it a more physiological approach to HPG axis stimulation than direct GnRH or gonadotropin administration. Kisspeptin also has direct roles in sexual arousal — fMRI studies show it activates limbic brain regions associated with sexual processing and romantic bonding.

• Dhillo et al. (2005) demonstrated kisspeptin-54 potently stimulated LH and FSH release in healthy men (Journal of Clinical Endocrinology & Metabolism)
• fMRI studies by Comninos et al. (2017) showed kisspeptin-54 enhanced brain processing of sexual and romantic stimuli in healthy men (Journal of Clinical Investigation)
• Research in women with hypothalamic amenorrhea showed kisspeptin restored LH pulsatility (Journal of Clinical Investigation, 2014)
• Studies demonstrated kisspeptin can trigger oocyte maturation for IVF, potentially replacing HCG as a trigger with lower ovarian hyperstimulation risk
• Kisspeptin administration in hypogonadal men produced dose-dependent increases in testosterone via LH stimulation
• Loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism, confirming kisspeptin's essential role in puberty and reproduction

• Fertility/LH stimulation: 1–10 mcg/kg IV or subcutaneous injection (clinical research doses)
• HPG axis support: 100–500 mcg subcutaneous injection daily or every other day
• Some protocols use 200 mcg twice weekly for testosterone optimization
• Pulsatile administration (every 60–90 minutes) most closely mimics physiology but is impractical outside research settings
• Cycle: 4–8 weeks, assess hormonal response via blood work
• Morning dosing preferred to align with physiological GnRH pulsatility
• Can be combined with gonadorelin for multi-level HPG axis support

Known Side Effects

• Facial flushing (common, transient — related to rapid gonadotropin release)
• Headache (mild, typically during first few doses)
• Injection site discomfort
• Potential for ovarian hyperstimulation in women (clinical fertility context)
• Transient nausea
• Theoretical risk of HPG axis desensitization with continuous high-dose use

Safety Profile

Kisspeptin-10 has been studied in Phase I and II clinical trials with a good safety profile. As the physiological master switch for reproduction, it produces effects consistent with HPG axis activation. The main safety consideration is avoiding continuous high-dose administration, which could paradoxically suppress the reproductive axis (similar to continuous GnRH). In women, there is a risk of ovarian hyperstimulation comparable to other fertility agents. Contraindicated in sex-hormone-dependent cancers (breast, prostate, ovarian), pregnancy, and in children (could trigger precocious puberty). Monitor LH, FSH, testosterone/estradiol, and gonadal function during use. Overall, well-tolerated at research doses.

Week 1: Possible facial flushing after injection. LH levels rise acutely. Subtle increases in libido may be noticed. Week 2–4: Testosterone levels begin rising (in men). Enhanced sexual responsiveness and arousal. Improved mood and energy associated with optimized sex hormones. Weeks 5–8: Full hormonal optimization achieved. Libido, energy, and well-being improved. Fertility parameters (sperm count, motility) may improve in men with prior suppression. Women may notice improved cycle regularity. Effects are reversible upon discontinuation.

Prices sourced from peptides.gg marketplace. Prices may vary.